HAEMATO: HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company Huons Bio Pharma Co., Ltd. ("Huons BioPharma"), based in Seoul, Korea. For this purpose, Huons BioPharma and HAEMATO have concluded an exclusive licence and supply agreement. With the purchase of a botulinum toxin product under its own brand, HAEMATO is further expanding its "Lifestyle & Aesthetics" division. Due to the partnership with Huons BioPharma, HAEMATO's "time-to-market" is considerably shortened, as the otherwise lengthy in-house development of a toxin is not necessary.
The "International Society of Aesthetic Plastic Surgery" shows in its study1 published in January 2021 that the botulinum toxin treatment is the most performed non-invasive beauty treatment worldwide. Since 2015, the number of treatments with botulinum toxin products has increased by more than 35% - a trend that will continue in the future due to the increased acceptance of beauty treatments. The product will ensure the long-term supply of the parent company, M1 Kliniken AG (ISIN: DE000A0STSQ8), one of the leading providers of beauty treatments in Europe, with an attractively priced botulinum toxin product. In addition, the product is to be distributed in all European markets.
About Huons BioPharma:
1 International Society of Aesthetic Plastic Surgery (2021): ISAPS International Survey On Aesthetic/Cosmetic Procedures
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
End of Media Release
Issuer: HAEMATO AG
Key word(s): Trades
25.10.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
|Phone:||+49 (0)30 897 30 86 70|
|Fax:||+49 (0)30 897 30 86 79|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||1243110|
|End of News||DGAP Media|